Literature DB >> 21733731

Usefulness of routine hepatitis C and hepatitis B serology in the diagnosis of recent-onset arthritis. Systematic prospective screening in all patients seen by the rheumatologists of a defined area--brief report.

Thiphaine Ansemant1, Paul Ornetti, Jean-François Garrot, Françoise Pascaud, Christian Tavernier, Jean-Francis Maillefert.   

Abstract

OBJECTIVE: Previous studies evaluating the usefulness of systematic screening for hepatitis B and C in patients with recent-onset arthritis suffered from a major bias since they were conducted in hospitals. The objective of the present study was to evaluate the relevance of such screening, performed by hospital and office-based rheumatologists of a defined area, in the diagnosis of arthritis or inflammatory polyarthralgia of less than 1 year duration.
METHODS: The CRRRI is a network which includes most hospital and office-based rheumatologists of an area with a population of 506,755 inhabitants. All patients seen by the CRRRI participants in their usual practice between March 2008 and December 2010 for inflammatory polyarthralgia, mono-, oligo-, or polyarthritis of less than 1 year duration were included. Patients' serum samples were screened for the presence of anti-hepatitis C virus (HCV) antibodies, with positive samples further evaluated for HCV-RNA with a reverse transcriptase-polymerase chain reaction, and for the presence of hepatitis B virus (HBV) infection.
RESULTS: Two hundred and thirty-three patients were included (162 women, 71 men; mean age of 50.6±15.8 years). Patients were evaluated for inflammatory polyarthralgia (n=51), monoarthritis (n=21), oligoarthritis (n=35) or polyarthritis (n=126) lasting for a mean 19.8±29.8 weeks. No new HCV or HBV infection diagnosis was done.
CONCLUSION: In this study not suffering from a hospital-selection bias, screening for hepatitis C and B infection was not helpful in the diagnosis process of recent-onset arthritis. KEY MESSAGES: Systematic hepatitis B and C serology is not relevant in patients with recent-onset (<1 year) arthritis.
Copyright © 2011 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733731     DOI: 10.1016/j.jbspin.2011.05.019

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  5 in total

Review 1.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

2.  [Virus-associated arthritis].

Authors:  F Günther; M Fleck; B Bach
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.530

3.  Hepatitis B Serology in Patients with Rheumatic Diseases.

Authors:  Martin Feuchtenberger; Arne Schäfer; Axel Philipp Nigg; Michael Rupert Kraus
Journal:  Open Rheumatol J       Date:  2016-08-31

Review 4.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

5.  Post SARS-CoV-2 infection reactive arthritis: a brief report of two pediatric cases.

Authors:  Reza Sinaei; Sara Pezeshki; Saeedeh Parvaresh; Roya Sinaei; Reza Shiari; Mehrnoush Hassas Yeganeh; Nasrin Bazargn; Nava Gharaei
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.